SCHEMBL4112669

SCHEMBL4112669

COc1ccc(NC(=O)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.81
RAB9A P51151 5/20 0.81
SMN1; SMN2 Q16637 4/20 0.81
MEN1 O00255 6/20 0.72
KMT2A Q03164 6/20 0.72
MAPT P10636 6/20 0.70
HTT P42858 1/20 0.69
CNR1 P21554 3/20 0.68
ALDH1A1 P00352 3/20 0.68
FPR2 P25090 2/20 0.68
LMNA P02545 2/20 0.68
L3MBTL1 Q9Y468 1/20 0.67
KDM4E B2RXH2 1/20 0.67
SAE1 Q9UBE0 1/20 0.67
UBA2 Q9UBT2 1/20 0.67
GRIK1 P39086 1/20 0.67
TP53 P04637 3/20 0.65
ESR2 Q92731 1/20 0.65
NOX1 Q9Y5S8 1/20 0.65
TSHR P16473 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11092496 0.90 RAB9A (1.00) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL14021839 0.85 MEN1 (0.65) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL17628550 0.85 RAB9A (0.88) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL16562239 0.85 SMN1; SMN2 (0.77) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2121351 0.84 NPC1 (0.83) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL11122035 0.84 NPC1 (0.83) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL3786216 0.84 SMN1; SMN2 (0.71) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL11048619 0.84 MEN1 (0.76) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4741253 0.84 MEN1 (0.76) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL22103801 0.84 TP53 (0.75) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20240409504-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER DUKE UNIVERSITY 2024-12-12 US disclosed
US-20240317727-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER DUKE UNIVERSITY 2024-09-26 US disclosed
US-12098117-B2 Compositions and methods for the treatment of cancer DUKE UNIVERSITY (US) 2024-09-24 US disclosed
CN-109627429-B Preparation method of high molecular weight poly (gamma-butyrolactone) 青岛博远高分子材料研究院有限公司 2024-04-16 CN disclosed
CN-116789943-A Unsaturated polylactic acid copolyester and preparation method thereof 浙江恒逸石化研究院有限公司 2023-09-22 CN disclosed
US-20220106265-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER DUKE UNIVERSITY (US) 2022-04-07 US disclosed
EP-3894392-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER Duke University (US) 2021-10-20 EP disclosed
WO-2020123675-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER DUKE UNIVERSITY (US) 2020-06-18 WO disclosed
WO-2019149086-A1 POLYETHER-B-POLY (γ-BUTYROLACTONE) BLOCK COPOLYMER AND PREPARATION METHOD THEREFOR 青岛科技大学 2019-08-08 WO disclosed
US-9932300-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-03 US disclosed
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-11-03 US disclosed
US-9421211-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-08-23 US disclosed
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20080200530-A1 Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy ARENA PHARMACEUTICALS, INC. 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409504-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER HSF1, HSP90AB1, HSP90AA1 NPC1 1296/4885RAB9A 3091/4885SMN1; SMN2 2520/4885
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation NSUN2, EIF2AK2, RNGTT NPC1 1310/4885RAB9A 2490/4885SMN1; SMN2 850/4885
US-20080200530-A1 Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy HTR2A, HTR5A, HTR1A NPC1 1831/4885RAB9A 2961/4885SMN1; SMN2 1174/4885
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 NPC1 927/4885RAB9A 815/4885SMN1; SMN2 4056/4885
US-12098117-B2 Compositions and methods for the treatment of cancer HSF1, HSP90AB1, HSP90AA1 NPC1 1296/4885RAB9A 3091/4885SMN1; SMN2 2520/4885
US-20240317727-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER HSF1, HSP90AB1, HSP90AA1 NPC1 1296/4885RAB9A 3091/4885SMN1; SMN2 2520/4885
US-20220106265-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER HSF1, HSP90AB1, HSP90AA1 NPC1 1296/4885RAB9A 3091/4885SMN1; SMN2 2520/4885
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION NSUN2, EIF2AK2, RNGTT NPC1 1310/4885RAB9A 2490/4885SMN1; SMN2 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.